Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.64 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.64 |
| ▸ | AHCY | P23526 | 8/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800381 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL13134675 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL13173634 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL18520788 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL16300875 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL800346 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL21413837 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL22326787 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL22326785 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 | |
| SCHEMBL800204 | 1.00 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117825480-A | Biomarker screening method based on broad-target metabonomics and machine learning, and selected chronic kidney disease biomarker group and application thereof | 武汉大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-117007703-A | Diagnostic marker for urinary calculus, diagnostic kit and application thereof | 中国人民解放军海军军医大学第一附属医院 | 2023-11-07 | — | — | CN | disclosed |
| CN-116790461-A | Method for producing hydrogen corrinate | 中国科学院天津工业生物技术研究所 | 2023-09-22 | — | — | CN | disclosed |
| CN-116381072-A | Biomarker for identifying sporadic gout and frequent gout and application thereof | 青岛大学附属医院 | 2023-07-04 | — | — | CN | disclosed |
| CN-111253417-B | Synthesis and application of purine derivative | 大连民族大学 | 2022-03-25 | — | — | CN | disclosed |
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3262057-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| WO-1999026657-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASE | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0824345-A1 | S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY | ORIDIGM CORPORATION (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5714459-A | ADMINISTERING TO TREAT DEMYELINATION IN MAMMALS | MYELOS NEUROSCIENCES CORP. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5700909-A | FOR STIMULATING NEURAL CELL OUTGROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-12-23 | — | — | US | disclosed |
| US-5696080-A | ABILITY TO PROMOTE INCREASED NEURAL OUTGROWTH OR INCREASED MYELINATION ACTIVITY | MYELOS NEUROSCIENCES CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0720482-A4 | PROSAPOSIN AND CYTOKINE-DERIVED PEPTIDES AS THERAPEUTIC AGENTS | UNIV CALIFORNIA (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5571787-A | Prosaposin as a neurotrophic factor | MYELOS CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996033703-A2 | S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY | ORIDIGM CORPORATION (US) | 1996-10-31 | — | — | WO | disclosed |
| EP-0720482-A1 | PROSAPOSIN AND CYTOKINE-DERIVED PEPTIDES AS THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995003821-A1 | PROSAPOSIN AND CYTOKINE-DERIVED PEPTIDES AS THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | PRMT5 1543/4885WDR77 2428/4885AHCY 2087/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PRMT5 1552/4885WDR77 2124/4885AHCY 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.